NextGen Homologous Recombination Deficiency Panel , Blood + Tissue block

What Is a NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block? 

The NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block is an advanced genetic test that uses next-generation sequencing (NGS) technology to analyse your blood sample. This test examines circulating tumour DNA (ctDNA) in your blood to identify genetic changes in cancer cells without needing a tissue biopsy from the tumour itself. The test helps detect whether cancer cells have a faulty DNA repair system called homologous recombination deficiency, which makes it difficult for cancer cells to repair their own damaged DNA. 

What Does the NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block, Measure? 

This NGS sequencing test measures several important genetic markers to guide personalised cancer treatment: 

• Gene mutations: Identifies harmful changes in genes responsible for DNA repair, including BRCA1, BRCA2, and other genes in the homologous recombination pathway.
  • Genomic Instability Score (GIS): Measures the level of genetic "scarring" or instability in cancer cells.
  • Loss of Heterozygosity (LOH): Detects loss of one copy of genes or chromosomal regions. 
  • Telomeric Allelic Imbalance (TAI): Identifies imbalances in DNA at chromosome ends. 
  • Large-scale State Transitions (LST): Counts major breaks or rearrangements across chromosomes. 
  • HRD status: Determines if the tumour is HRD-positive or HRD-negative for treatment planning. 

NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block: Who Needs It and Why It's Done 

What Symptoms May Call for a NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block? 

This test is ordered after a cancer diagnosis rather than for specific HRD symptoms. The symptoms that lead to initial cancer diagnosis may include persistent bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, and frequent urination. 

Who Should Get a NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block? 

Your oncologist may recommend this test if you are a patient with high-grade ovarian cancer. 

Why Is a NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block, Done? 

This test is performed to determine whether your cancer is likely to respond to specific targeted therapy drugs called PARP inhibitors, enabling your doctor to choose the most effective personalised treatment plan. 

Importance of a NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block 

This test represents a cornerstone of personalised medicine in cancer care. Instead of using a one-size-fits-all treatment approach, the HRD testing allows your doctor to understand the unique genetic makeup of your tumour. If your test shows HRD-positive results, you may be an excellent candidate for PARP inhibitor therapy, which can lead to better outcomes, longer remission periods, and improved survival.  

If the result is HRD-negative, your doctor can choose different treatment strategies, potentially saving you from ineffective therapies and their associated side effects. This targeted approach ensures you receive the most appropriate treatment for your specific cancer type. 

NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block Booking & Reports – Metropolis Healthcare India 

How to Book a NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block? 

1. Simple Online Booking 
   Booking can be done through the Metropolis Healthcare App or website. Select the 'NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block', choose a convenient time slot, and provide your address for a blood test at home. You can also visit the nearest Metropolis Lab if you prefer to give the blood sample directly at the lab. However, for the tissue sample (FFPE Block), you will need to visit the Metropolis Lab. 
    
2. Safe Home Sample Collection 
   Our trained phlebotomists ensure the timely collection of your sample while strictly following all safety and hygiene protocols. 
    
3. Sample Tracking Updates 
   Stay informed at every step. From collection to testing, you can track your sample directly through the Metropolis Healthcare website.
    
4. Accurate Laboratory Testing 
   Your sample is processed at our NABL & CAP accredited laboratories, where expert technicians ensure accurate results. 
    
5. Quick & Easy Reports 
   Receive your test reports promptly via email, WhatsApp, or by downloading them directly from the Metropolis Healthcare website or app. 

Is Home Sample Collection for the NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block, Available Near You? 

Yes, Metropolis Healthcare brings this advanced genetic testing directly to your doorstep through our comprehensive home blood sample collection service. Our trained phlebotomists follow strict safety protocols while collecting your blood sample in the comfort of your home. This convenient service eliminates the need for hospital visits during your treatment journey. However, you will need to visit the Metropolis Lab for the submission of a tissue sample (FFPE Block), as it is collected from your doctor or the hospital. 

How Long Does It Take to Get a NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block, Report? 

Reports are usually available within 4 weeks once the sample reaches the pathology lab. 

Note: Reporting time may vary depending on your location. 

Where Can I See or Get the NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block, Results? 

Test results from Metropolis Healthcare can be accessed through multiple convenient channels. You can log in to the Metropolis website using your credentials or use the Metropolis Healthcare App to view and download your reports. Additionally, test reports are sent via email or WhatsApp, and you also have the option to collect a physical copy directly from the lab. 

Interpreting NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block, Results 

What Your NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block, Results May Indicate 

Your test results will show the genetic status of various DNA repair genes and provide treatment guidance: 

Conditions that May Affect NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block, Accuracy 

Several factors should be considered when interpreting your HRD testing results: 

• Ongoing cancer treatments: Chemotherapy or radiation therapy may affect circulating tumour DNA levels.
  • Sample timing: The amount of circulating tumour DNA can vary depending on disease stage and treatment status.
  • Blood sample quality: Haemolysis, lipemia, or improper storage can impact test accuracy. 
  • Tumour burden: Low levels of circulating tumour cells may affect detection sensitivity. 
  • Recent medical procedures: Surgery or biopsies may temporarily alter circulating DNA patterns. 
  • Medication interference: Certain drugs may affect DNA analysis, though this is rare for genetic testing. 

How Is a NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block, Done? 

The test follows a systematic process to ensure accurate genetic analysis: 

• A healthcare professional cleans your arm with an antiseptic wipe.
  • An elastic band is tied around your upper arm to make the veins more visible.
  • A sterile needle is inserted into a vein to collect 4 ml of blood into a special EDTA tube. 
  • The blood sample is carefully labelled and prepared for transport to the pathology lab. 
  • Advanced next-generation sequencing technology analyses the genetic material. 
  • Sophisticated computer algorithms identify and classify genetic variants. 
  • Results are interpreted by expert pathologists according to clinical guidelines. 

How Should You Prepare for a NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block? 

Preparing for this test is straightforward and requires minimal preparation: 

• No fasting required: You can eat and drink normally before the test.
  • Continue regular medications: Do not stop any prescribed treatments unless specifically instructed by your doctor.
  • Bring required documents: Ensure you have your clinical history, histopathology reports, and medical prescription. 
  • Stay hydrated: Drink adequate water to make blood collection easier. 
  • Inform your doctor: Share information about all current treatments, supplements, and health conditions. 
  • Wear comfortable clothing: Choose clothing that allows easy access to your arm for blood collection. 

Diseases that a NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block, Can Help Detect 

This panel provides valuable information for managing several cancer types: 

• High-grade serous ovarian cancer: Primary indication for HRD testing and PARP inhibitor therapy
  • Hereditary breast and ovarian cancer syndrome: Identifies BRCA1/BRCA2 mutations and family health risk
  • Triple-negative breast cancer: Helps guide treatment decisions in aggressive breast cancer subtypes 
  • Pancreatic adenocarcinoma: Assists in identifying patients who may benefit from targeted therapy 
  • Castration-resistant prostate cancer: Guides treatment selection in advanced prostate cancer 
  • Fallopian tube and primary peritoneal cancers: Closely related to ovarian cancer management 
  • Other solid tumours: May provide insights for various cancers with HRD characteristics 

NextGen Homologous Recombination Deficiency Panel, Blood + Tissue Block/Packages that You Can Book With Metropolis Healthcare 

Here are some of the related comprehensive cancer screening packages available at Metropolis Healthcare to support your diagnostic needs: